Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Fatty Liver

• A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
• A Phase IV Study of Huazhi Rougan Granule
• A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.
• To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .
• A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steat
• Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis
• Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
• A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese
• Benefits of Trimetazidine in MAFLD Pateints
• ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial
• A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
• Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies
• Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
• Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)
• Dexamethasone/Pancreatic Clamp P&F
• The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
• A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
• Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis
• Dose Exploration Study of GSK4532990 in Participants With NASH or Suspected NASH
• Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
• A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
• Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
• A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
• Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial)
• Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
• A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
• Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
• A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH
• Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity
• Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
• A Clinical Study of Efinopegdutide in in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
• A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
• Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
• Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
• A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
• Semaglutide in Nonalcoholic Fatty Liver Disease
• A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
• Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）
• Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
• Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
• Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
• A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
• SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity
• Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
• A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men
• Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steatohepatitis
• Glycemic Effect of Diazoxide in NAFLD
• A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
• Pancreatic Clamp in NAFLD
• Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
• Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients
• A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
• Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
• A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
• A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects
• The SLIM LIVER Study
• A Study in Participants With Non-cirrhotic NASH With Fibrosis
• HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)
• HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
• Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis
• Ketotifen in Non-Alcoholic Fatty Liver Disease Patients
• Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients
• Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
• N-acetyl Cysteine and Patients With Non-alcoholic Fatty Liver Disease
• Phase 2b Study of GSK4532990 in Adults With NASH
• High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease
• Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia
• Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients With Non-alcoholic Steatohepatitis
• Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
• Phase 1 Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
• FTIH of ECC4703 in Healthy Volunteers
• Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
• Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD
• A Study to Evaluate the Efficacy and Safety of ALN-HSD in Adult Participants With Non-alcoholic Steatohepatitis (NASH) With Fibrosis With Genetic Risk Factors
• First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease
• Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
• Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
• Non-alcoholic Fatty Liver Disease and Its Treatment
• Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
• MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
• Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
• Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.
• Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
• A Phase 2a Clinical Study to Evaluate the Safety, Efficacy, PK and PD of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed (NASH)
• A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
• A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis
• A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
• A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis.
• The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: A Pilot Study
• Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NASH
• Phase 2a Study of HPG1860 in Subjects With NASH
• A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease
• Quantifying Hepatic Mitochondrial Fluxes in Humans
• A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
• Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
• Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis
• Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic Steatohepatitis
• Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
• Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
• Semaglutide vs Sitagliptin
• A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
• Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
• Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
• A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia
• Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
• Norursodeoxycholic Acid vs. Placebo in NASH
• Liraglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
• A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
• A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects
• The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules
• Anti-diabetic Drugs and Fatty Liver Management
• A Study of JNJ-75220795 in Japanese Participants
• A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
• PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
• Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
• Digoxin In Treatment of Alcohol Associated Hepatitis
• FTIH Study of ECC0509 in Healthy Volunteers
• Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
• ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
• Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients
• Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
• ALT-801 DDI Study in Healthy Volunteers
• Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
• A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
• A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224
• A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
• Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
• A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
• AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
• First-in-Human Study of SRT-015 in Healthy Subjects.
• Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
• A Study of BOS-580 in Obese Subjects at Risk for Nonalcoholic Steatohepatitis (NASH)
• Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
• The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
• Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
• Study in Healthy Adults Evaluating PF-07202954
• Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution
• A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis
• A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
• Estrogen Administration for the Treatment of NASH in Postmenopausal Women
• The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects
• Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
• A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
• Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
• Vitamin E Dosing Study
• Study to Evaluate MET642 in Patients With NASH
• Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout
• A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
• A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
• Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
• A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
• S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease
• FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
• Multiple Ascending Dose Study of HU6 in High BMI Volunteers
• Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)
• Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
• Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
• A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
• Statins for the Treatment of NASH
• Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction
• Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
• Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
• Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
• Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome.
• Combined Active Treatment in Type 2 Diabetes With NASH
• A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)
• A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
• A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
• A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
• ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
• A Study of EDP-297 in Healthy Subjects
• Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
• Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects
• GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver
• Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH)
• Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis(NASH)
• Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects
• Low-Dose Pioglitazone in Patients With NASH (AIM 2)
• A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
• A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects
• A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
• Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases
• Ascending Dose Study of HU6 in Healthy Volunteers
• The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects
• Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
• Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
• To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
• A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH
• A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With
• Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
• A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH
• Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
• LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
• Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
• The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance
• Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
• A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis
• Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
• Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)
• Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
• Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
• A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients
• The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects
• An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NAS
• Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
• A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
• Safety and Tolerability of Oral Proglumide for NASH
• Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects
• Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis
• A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
• Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)
• Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics
• A Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH)
• Curcumin for Pediatric Nonalcoholic Fatty Liver Disease
• A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
• The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis
• Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.
• A Phase 2b Study of Icosabutate in Fatty Liver Disease
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
• A Multiple Ascending Dose Study of BIO89-100 in Subjects With Biopsy Confirmed NASH or NAFLD and at High Risk of NASH
• Vitamin D in Fatty Liver Disease
• Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
• A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
• A Study of FT 4101 in Overweight/Obese Participants With NASH
• A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
• A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
• Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
• A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
• A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
• A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
• Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
• Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
• A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
• To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes
• Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
• Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
• A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
• Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
• Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
• An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD
• SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
• The Effect of Curcumin on Liver Fat Content in Obese Subjects
• Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
• Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism
• Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
• Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery
• Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT
• Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
• Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
• Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease
• A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
• A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
• A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
• Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
• A Study of Multiple Doses of HM15211 in Obese Subjects With NAFLD
• Clinical Study to Evaluate Effect on Fatty Liver and Safety of Trehalose
• Dapagliflozin Efficacy and Action in NASH
• Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
• Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
• An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function
• Vitamin E for NASH Treatment in HIV Infected Individuals
• Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis
• A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
• An Evaluation of the Safety and Efficacy of NTZ on Collagen Turnover in NASH Patients With Fibrosis
• Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
• Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver
• Safety, Tolerability and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With NAFLD
• Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)
• Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
• Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
• Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
• Spironolactone Therapy In Young Women With NASH
• A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
• Hepatic Metabolic Changes in Response to Glucagon Infusion
• Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
• 2-Week Study In People With Nonalcoholic Fatty Liver Disease
• Study of Gemcabene in Adults With FPLD
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
• Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway
• A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
• Losartan for the Treatment of Pediatric NAFLD
• Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
• Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
• A Study of Experimental Medication BMS-986036 Given to Healthy Participants
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
• Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
• Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease
• Gemcabene for the Treatment of Pediatric NAFLD
• Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
• A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
• Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics
• Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
• Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD
• Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
• Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
• A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
• A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
• Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
• An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH
• A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
• Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
• Levothyroxine for Non-Alcoholic Fatty Liver Disease (NAFLD)
• 6-week Safety and PD Study in Adults With NAFLD
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
• The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease
• Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
• Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
• A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis
• Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
• Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
• Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV
• Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
• A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
• Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
• Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
• AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
• Phase 2b Study in NASH to Assess IVA337
• Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.
• Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
• Silymarin in NAFLD
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
• Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis
• Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
• Safety And Efficacy Study Of Orally Administered DS102 In Patients With NAFLD
• Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
• A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
• Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
• Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)
• Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
• Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
• Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
• Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)
• Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone
• Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
• Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)
• Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
• AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.
• Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
• Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
• A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
• Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
• A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
• Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents
• Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
• SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis
• Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
• Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
• Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
• Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
• Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent
• CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
• Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
• Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics
• SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
• Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
• Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
• Cardiometabolic Effects of Eplerenone in HIV Infection
• A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
• Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
• Tocotrienol Against the Progression of End Stage Liver Disease
• A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis
• A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
• The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease
• Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
• Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis
• Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
• Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients
• Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study
• Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
• Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study
• JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
• Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
• A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
• Fatty Liver Study in Patients With Type II Diabetes
• A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
• ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
• The Effects of PXR Activation on Hepatic Fat Content
• Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes
• Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
• Effects of Pitavastatin on Insulin Sensitivity and Liver Fat
• Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM
• Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
• A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
• The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver Disease
• A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
• A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients
• A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
• Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI
• Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD
• Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects
• Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin
• The Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis
• Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
• Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
• Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
• Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients
• Tesamorelin Effects on Liver Fat and Histology in HIV
• The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients
• Liver and Fat Regulation in Overweight Adolescent Girls
• Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
• MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
• DHA and Vitamin D in Children With Biopsy-proven NAFLD
• A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
• Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis
• Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
• Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
• Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients
• Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
• Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
• Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment
• Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
• Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
• Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
• Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
• Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS)
• Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection
• Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
• The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease
• Amlexanox for Type 2 Diabetes and Obesity
• Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
• Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
• Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease
• Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
• Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
• Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease
• Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group
• Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
• Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
• Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
• Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
• Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
• Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
• The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine
• Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
• Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis
• Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis
• Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis
• Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D
• Ursodeoxycholic Acid in Bariatric Surgery
• Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin
• Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
• A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
• Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
• Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
• Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
• Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis
• Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease
• Regression of Myocardial Steatosis by Nebivolol
• Rifaximin in Fatty Liver Disease
• Insulin Resistance in Non-alcoholic Fatty Liver Disease
• Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
• Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease
• Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial
• The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis
• The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
• A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease
• The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
• Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes
• Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)
• Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis
• Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
• Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)
• Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome
• A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)
• Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
• Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients
• Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease
• Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
• Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease
• Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
• The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis
• Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis
• Anti-Fibrotic Effects of Losartan In Nash Evaluation Study
• Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
• Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
• University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
• Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
• Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
• Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)
• Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics
• Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
• Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
• Pioglitazone on Pancreatic Steatosis and Bone Health
• Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
• Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
• A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)
• Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)
• Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids
• Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
• Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
• Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
• Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
• Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)
• Study of Fish Oil to Reduce ALT Levels in Adolescents
• Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
• Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis
• Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
• A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)
• Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis
• A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831
• Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
• Role of Exenatide in NASH-a Pilot Study
• Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease
• Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)
• Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
• Betaine in Patients With Nonalcoholic Steatohepatitis
• Effects of Alanine in Patients With Nonalcoholic Steatohepatitis
• An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
• An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
• Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
• Study of INT-747 in Patients With Diabetes and Presumed NAFLD
• A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
• Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content
• Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis
• Cholic Acid for Hepatic Steatosis in Lipodystrophy
• A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)
• Pioglitazone to Treat Fatty Liver in People With HIV Infection
• Phase I Trial of Silymarin for Chronic Liver Diseases
• Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
• Metformin in Non-Alcoholic Fatty Liver Disease
• Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver
• Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
• Obesity and Nonalcoholic Fatty Liver Disease
• Insulin Resistance in Non-alcoholic Fatty Liver Disease
• Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
• Development of a Breath Test for Monitoring Patients With Liver Disease
• Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
• Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus
• Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
• S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis
• The Effect of a Probiotic on Hepatic Steatosis
• The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics
• Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
• Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)
• Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
• Treating Nonalcoholic Steatohepatitis With Pioglitazone
• Treatment of Nonalcoholic Steatohepatitis With Pioglitazone
• Randomized Study of the Use of Intravenous Choline Supplementation in Long Term Total Parenteral Nutrition